Patents by Inventor Steven J. Collins

Steven J. Collins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CaM Kinase II Inhibitor Improves Retinoic Acid Therapy and Inhibits the Proliferation of Myeloid Leukemia Cells
    Publication number: 20080255244
    Abstract: A method of treating a cancer (e.g., myeloid leukemia) in a subject in need thereof, is carried out by administering the subject a CaM kinase II (CaMK II) inhibitor. In some embodiments, the CaMK II inhibitor is administered concurrently with a retinoid. In some embodiments, the CaMK II inhibitor is CaMK II gamma inhibitor. Compositions and formulations useful for carrying out such methods are also described.
    Type: Application
    Filed: April 8, 2008
    Publication date: October 16, 2008
    Inventors: Steven J. Collins, Jutong Si
  • Isolated polynucleotide molecules encoding CTCF, a CCCTC-binding factor
    Patent number: 5972643
    Abstract: Polynucleotide molecules encoding CTCF are isolated and purified and sequenced. The CTCF proteins and antibodies thereto can be used to identify mutant CTCFs in methods of diagnosis.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 26, 1999
    Assignees: Fred Hutchinson Cancer Research Center, Cancer Research Campaign Technology, Ltd.
    Inventors: Victor L. Lobanenkov, Paul E. Neiman, Elena M. Klenova, Graham H. Goodwin, Galina N. Filippova, Steven J. Collins, Robert H. Nicolas
  • Creating novel hematopoietic cell lines by expressing altered retinoic acid receptors
    Patent number: 5830760
    Abstract: Methods for establishing continuous SCF dependent lympho-hematopoietic progenitor cell lines capable of differentiating into erythroid, myeloid, and B lymphocytic lineages, and GM-CSF dependent neutrophil progenitor cell lines capable of differentiating into neutrophils but not into monocytes, mast cells, or basophils, by introducing into bone marrow, fetal spleen, fetal liver, or other hematopoietic myeloid cells nucleic acid encoding a dominant negative suppressor of a retinoic acid receptor-alpha and a selectable marker, and culturing the recombinant cells in culture medium containing SCF or GM-CSF, agents allowing for selective growth of the recombinant cells, and a level of retinoic acid of less than about 10.sup.-8 M to about 10.sup.-9 M in the case of establishing neutrophilic progenitor cell lines. Addition of a retinol compound induces the latter cell line to differentiate into neutrophils.
    Type: Grant
    Filed: January 26, 1996
    Date of Patent: November 3, 1998
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Schickwann Tsai, Steven J. Collins
  • Writing implement and cap therefor having an integral bookmark
    Patent number: 5829903
    Abstract: A writing implement includes a ball point pen and corresponding cap at one end, and a highlight marker and corresponding cap at the other end. The highlight marker cap includes an integral blade portion which functions as a bookmark. The writing implement and cap are adapted to be slidably received over the spine of a book wherein the blade portion of the highlight marker cap extends downwardly between the pages of the book, and the body of the writing implement extends downwardly along the outside of the book spine.
    Type: Grant
    Filed: April 7, 1994
    Date of Patent: November 3, 1998
    Inventor: Steven J. Collins
  • Combination writing instrument and bookmark
    Patent number: D355933
    Type: Grant
    Filed: January 18, 1994
    Date of Patent: February 28, 1995
    Inventor: Steven J. Collins
  • Writing implement
    Patent number: D369184
    Type: Grant
    Filed: July 10, 1995
    Date of Patent: April 23, 1996
    Inventor: Steven J. Collins